What’s New in (Bio)Pharma?
A spectroscopic near real-time PAT tool, saying “bye bye” to batch, and $100 million for Carol Robinson’s native mass spec tech…
James Strachan | | News
PAT on the back
Researchers from Vienna University of Technology used quantum cascade laser-based mid-infrared (QCL-IR) spectroscopy for in-line monitoring of proteins from preparative liquid chromatography – an essential unit operation in downstream processing of complex biopharmaceuticals. The QCL-IR method, which the authors described as a “near real-time PAT tool,” was able to detect whole proteins quickly and accurately, while also providing additional information about their secondary structure.
Saying “bye” to batch
Many modern industries – automobile assembly lines, petroleum refineries and steel mills – have adopted continuous manufacturing, yet biopharmaceuticals are usually produced via batch processing. With promises of higher productivity, greater quality consistency, and reduced facility footprint, what’s the hold up? According to researchers from the Indian Institute of Technology Delhi, technology is key. In a recent review, the authors highlighted the various enablers, including novel continuous chromatography systems and data analysis tools.
When mass spec meets mIF
NeoGenomics has expanded its strategic partnership agreement with Biognosys AG. The companies have designed a new approach to analyze proteins in tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors. They use Biognosys' TrueDiscovery proteomics platform, which is based on proprietary mass spectrometry (MS) technology, with NeoGenomics’ multiplexed immunofluorescence (mIF) technology.
REBEL with a cause
There is an increasing need for predictive modeling and real-time control of the development process to improve efficiency and product quality consistency in the biopharma industry. In light of this trend, CPI researchers are using REBEL (908 Devices’ capillary-electrophoresis and high-pressure MS-based desktop device) for at-line cell culture media analysis. The overall aim of the project is to optimize mammalian cell culture media and feeding strategies to improve growth, protein titer and protein quality attributes.
Also in the News...
OMass Therapeutics raises $100 million in series B financing to progress its drug discovery platform, OdyssION – a commercialization of Carol Robinson’s native mass spectrometry research. Link
Gore PharmBio introduces 116 ml and 232 ml protein capture devices with Protein A to increase productivity and throughput for antibody purification. Link
Thermo Fisher Scientific releases a new Raman spectroscopy analyzer for biopharmaceutical process monitoring, promising “fully automated in situ measurements.” Link
Bruker acquires Optimal Industrial Automation and Technologies – a UK-based developer of (bio)pharma process analytical technology, manufacturing automation, and quality assurance software. Link
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.
From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
